Century Therapeutics, Inc.

IPSC Nasdaq CIK: 0001850119

Company Information

Industry Biological Products, (No Diagnostic Substances)
SIC Code 2836
Entity Type operating
SEC Category Emerging growth company
State of Incorporation DE
Business Address 25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA, PA, 19104
Mailing Address 25 N 38TH STREET, 11TH FLOOR, PHILADELPHIA, PA, 19104
Phone 215-981-4000
Fiscal Year End 1231
EIN 842040295

Financial Overview

FY2025

-$9.58M
Net Income

Recent SEC Filings

Form Type Date Filed Document
8-K Current report of material events March 26, 2026 View on SEC
424B5 Prospectus supplement March 26, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report March 16, 2026 View on SEC
4 Insider stock transaction report March 13, 2026 View on SEC
4 Insider stock transaction report March 13, 2026 View on SEC
8-K Current report of material events March 12, 2026 View on SEC
10-K Annual financial report March 12, 2026 View on SEC
4 Insider stock transaction report March 11, 2026 View on SEC
4 Insider stock transaction report March 11, 2026 View on SEC

Annual Reports

10-K March 12, 2026
  • Developing innovative iPSC-derived cell therapies for challenging cancers and autoimmune conditions.
  • Strong cash reserve of $210.0 million expected to fund operations into late 2026 or early 2027.
View Analysis

Material Events

8-K Strategy Change January 23, 2026
High Impact
  • Avoided reverse stock split, signaling renewed investor confidence and organic stock price recovery.
  • Regained Nasdaq compliance, removing the immediate threat of delisting.
View Analysis

Insider Trading

BUY 4 insiders 9 recent transactions
View Full Insider Trading Profile

Related Companies

Companies in the same industry (SIC: 2836)

Investor Resources

Learn more about SEC filings and how to research public companies.

Important Disclaimer

This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.